Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can extra antibodies keep myeloma patients safer on powerful new drugs?

NCT ID NCT07094048

Recruiting now Disease control Sponsor: CHU de Quebec-Universite Laval Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving extra antibodies (immunoglobulins) can help prevent serious infections in people with multiple myeloma who are being treated with a new kind of immunotherapy called a BCMA-directed T cell engager. About 80 adults who have already tried at least one prior treatment will be enrolled. Researchers will compare two different target levels of antibodies in the blood to see which one better reduces severe infections over the first three months of therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA REFRACTORY RELAPSED MULTIPLE MYELOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Intégré de Cancérologie

    RECRUITING

    Québec, Quebec, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••